GlassScriptPhysician profile
Sheridan Scott Evans
NPI 1164439469
$1,607.91
in general payments reported to CMS, 2019-2025
25 companies · $56.62 in 2025
The $56.62 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $418 · 2021: $302 · 2022: $167 · 2023: $164 · 2024: $148 · 2025: $56.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $369.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $316.89 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $251.51 | 2019-2025 | Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.69 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $133.79 | 2020-2024 | Jardiance, Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $108.50 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $104.47 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.06 | 2020 | |
| Glaxosmithkline, LLC. | $59.42 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Supernus Pharmaceuticals, INC. | $56.93 | 2023-2024 | Qelbree, Qelbree |
| Jazz Pharmaceuticals INC. | $39.58 | 2021 | |
| Amgen INC. | $34.43 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $28.42 | 2023 | Linzess |
| Genentech USA, INC. | $26.71 | 2019-2020 | |
| Adlon Therapeutics L.P. | $24.09 | 2020 | |
| Corcept Therapeutics | $22.91 | 2025 | Korlym |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $17.70 | 2021 | |
| Ironshore Pharmaceuticals INC. | $16.90 | 2019 | |
| Bausch Health US, LLC | $16.80 | 2022 | |
| Eisai INC. | $16.72 | 2020 | |
| Almatica Pharma LLC | $16.10 | 2022 | |
| Corium, LLC | $14.06 | 2023 | Azstarys |
| Novartis Pharmaceuticals Corporation | $14.05 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $13.00 | 2023 | Rexulti |
| Allergan, INC. | $11.74 | 2019 | |
| Althera Pharmaceuticals LLC | $10.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheridan Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.